Comparison of Letermovir Versus Ganciclovir for Cytomegalovirus Prophylaxis in Pediatric Hematopoietic Stem Cell Transplant Recipients. (PubMed, Pediatr Blood Cancer) - Apr 20, 2025 - "Compared with those receiving letermovir, a significantly higher proportion of patients in the ganciclovir/valganciclovir group experienced dose modifications or discontinuation of CMV prophylaxis due to adverse effects. Letermovir shows great promise as a CMV prophylactic agent in pediatric HCT patients due to its favorable side effect profile."
Journal • Bone Marrow Transplantation • Cytomegalovirus Infection • Infectious Disease • Pediatrics • Transplantation
|
|
Alexis K Kuhn; Asmaa Ferdjallah; Catherine E Martin; Laura M Dinnes; Mira A Kohorst; Theresa Madigan
|